Skip to main content
main-content

29-09-2020 | ESMO 2020 | Conference coverage | Video

monarchE and PALLAS: A tale of two CDK4/6 inhibitors

George Sledge Jr speculates on the reasons for the contrasting results of the monarchE and PALLAS trials of adjuvant abemaciclib and palbociclib, respectively, in hormone receptor-positive, early-stage breast cancer (5:46).

Read transcript

Breast cancer at ESMO 2020

See all the news and expert interviews from the congress

Image Credits